ArticleCancer medicine2026
Survival Outcomes of Patients With Colorectal Cancer After Primary Surgery: A Population-Based Study in Hainan, China.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) is a major public health burden in Hainan Province due to its high incidence and mortality, yet region-specific prognostic data are lacking. This study evaluates prognostic factors in postsurgical CRC patients to guide localized prevention and treatment.
methodsWe conducted a retrospective cohort study of 265 patients undergoing first-time surgery for CRC between January 2015 and December 2021. Kaplan-Meier estimator and log-rank tests were performed to analyze the overall survival rates of CRC patients. Cox proportional hazards regression and the SHAP method were performed to determine the prognostic factors of CRC.
resultsThe study included 265 patients (mean age 63 ± 12.99 years), with 171 survivors (64.5%) and 94 deaths (35.5%). The 1-, 3- and 5-year overall survival rates of CRC patients were 93.0%, 82.1%, and 73.9%, respectively, from 2015 to 2021. In multivariable analysis, factors associated with increased mortality risk included advanced age (per 1 year increase: HR = 1.043, 95% CI: 1.018-1.069, p = 0.001), TNM stage III (HR = 11.46, 95% CI: 2.611-50.31, p = 0.001) and stage IV (HR = 15.06, 95% CI: 3.131-72.46, p = 0.001), increased tumor size (per 1 cm increase: HR = 1.267, 95% CI: 1.058-1.519, p = 0.01), positive vascular infiltration (HR = 2.399, 95% CI: 1.162-4.951, p = 0.018), elevated CEA levels (per 1 ng/mL increase: HR = 1.035, 95% CI: 1.012-1.059, p = 0.003), and increased CA125 levels (per 1 U/mL increase: HR = 1.013, 95% CI: 1.003-1.024, p = 0.014), while normal-weight (HR = 0.385, 95% CI: 0.168-0.880, p = 0.024) was associated with a better survival. No association was found between the expression of MSH2, MDR1, and GSTπ and the survival of the patients. The SHAP beeswarm plot highlighted TNM stage and age as the primary contributors to the model's predictions.
conclusionIncreased age, advanced TNM stage, larger tumor size, vascular invasion, and elevated CEA/CA125 were linked to poorer CRC prognosis, while normal BMI was protective. Further prospective studies are needed for validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.